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Abstract
Background: Targeting angiogenesis is nowadays one of the most promising approaches for
breast cancer. Bevacizumab (BEV), a VEGF-trap monoclonal antibody, was recently approved in
combination with paclitaxel (PAC) for the first line treatment of advanced breast cancer (ABC).
The activity of this combination in pretreated patients is not known.
Methods: Patients with pretreated ABC and progressive disease received BEV 10 mg/kg with PAC
135 mg/m2 every two weeks for six months and then maintenance with BEV 15 mg/kg every three
weeks until progression. This regimen was chosen for better patient convenience, while
maintaining the same dose intensity for both drugs.
Results: 42 patients were reviewed retrospectively (41 f, 1 m, mean age 57 years). Overall
response rate was 35.7%. Stable disease was observed in 45.2% of patients, whereas 14.3% of
patients progressed. The median overall survival was greater than 20 months, with a one year rate
of 83.4%. The median progression free survival was 12.1 months, with a one year rate of 51.8%.
Toxicity was in general acceptable.
Conclusion: This biweekly BEV/PAC combination seems to be active with acceptable toxicity in
pretreated ABC with an advantage over the weekly regimen regarding quality of life and
preservation of resources.
Background
Cancer is a major public health problem in most parts of
the world. It is estimated that about 565,650 Americans
died from cancer in 2008 and among these deaths, 40,480
were due to breast cancer in women. The new breast cancer
cases among American women for 2008 were 182,460 [1].
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Despite adjuvant chemotherapy, approximately 40--50%
of patients will develop recurrent and/or metastatic breast
cancer with angiogenesis, playing a central role in both
local tumour growth and distant metastasis formation [2].
Multiple angiogenic factors are commonly expressed by
invasive breast cancers and the 121-amino-acid isoform of
vascular endothelial growth factor (VEGF) predominates
[3].
Bevacizumab (BEV) (Avastin©, F. Hoffmann-La Roche
Ltd) is a recombinant humanized monoclonal antibody
against VEGF. Preclinical in vivo models demonstrate that
BEV inhibits growth of a variety of human cancer cell lines
in a dose dependent manner. In addition, by eliminating
the excess VEGF, the newly formed tumour vessels
become less permeable, resulting thus in reduction of
interstitial pressure. It has been shown that the latter effect
increases the diffusion of chemotherapeutic drugs in the
tumour and perhaps potentiates their activity [4].
In general, combination chemotherapy results in higher
response rates, longer times to progression [5] and in
some studies prolongs overall survival [6], when com-
pared to single agent therapy. In a phase III trial, the addi-
tion of BEV to capecitabine in patients previously treated
with anthracyclines and taxanes significantly increased
the objective response rate (9.1% vs. 19.8%, p = 0.001)
but not progression-free survival (4.2 vs. 4.9 months; haz-
ard ratio for disease progression, 0.98) or overall survival
(15.1 vs. 14.5 months) [7]. In another phase III trial by
Miller et al., paclitaxel plus bevacizumab significantly pro-
longed progression-free survival as compared with paclit-
axel alone (median, 11.8 vs. 5.9 months; p < 0.001) and
increased the objective response rate (36.9% vs. 21.2%, p
< 0.001) in the first line setting. The overall survival rate,
however, was similar in the two groups (median, 26.7 vs.
25.2 months; p = 0.16) [8].
The combination of BEV and PAC seems to be a promis-
ing combination and has been recently approved as initial
therapy for patients with ABC [8], nonetheless, literature
data regarding this combination in the 2nd+ line of treat-
ment are scarce.
In an effort to estimate the potential benefit of a prospec-
tive, randomized controlled trial comparing the combina-
tion of BEV and PAC to PAC alone in pre-treated patients,
we analysed the data of patients with ABC in the 2nd+ line
of treatment, who received a modified biweekly regimen
of BEV and PAC.
Methods
Patient eligibility and baseline evaluation
The population included male and female patients, 18
years of age or older, with histologically or cytologically
confirmed ABC, who had received at least one line of cyto-
toxic treatment for metastatic disease. Minimum time
interval from last administration of taxanes required for
inclusion was 9 months. For this retrospective analysis of
patient records, approval was obtained from the Institu-
tional Review Board (IRB,7996/361).
Additional inclusion criteria included Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0 or
1, no significant cardiovascular disease, no previous
thromboembolic disease and adequate renal, hepatic, and
hematologic function. The presence of measurable
tumour was not required for inclusion. Patients were
excluded if they had had another cancer within a period
of 5 years before initiation of 2nd line treatment, major
surgery within a period of 4 weeks before initiation of 2nd
line treatment, or if they had a non-healing wound or frac-
ture, an infection requiring parenteral antibiotics at the
time of initiation of 2nd line treatment. Patients were
excluded if they were on therapeutic anticoagulant agents,
non-steroidal anti-inflammatory agents. Use of prophy-
lactic low-dose anticoagulant agents wasn't considered as
an exclusion criterion.
Pre-treatment evaluation included a complete medical
history and physical examination, a full blood count, a
biochemical profile (SGOT, total bilirubin, creatinine),
prothrombin time, INR, and partial thromboplastin time.
In addition, computed tomography (CT) of the chest,
abdomen and brain or magnetic resonance imaging
(MRI), and assessment of performance status according to
ECOG were performed [9]. A complete blood count was
obtained regularly. An interim medical history, physical
examination and the laboratory tests listed above were
repeated prior to the start of each cycle of therapy.
Treatment plan
All patients received BEV 10 mg/kg with PAC 135 mg/m2
with appropriate premedication and supportive care,
every two weeks for six months and then maintenance
with BEV 15 mg/kg every three weeks until progression.
This regimen was chosen instead of the established one
(weekly PAC) for better patient convenience, while main-
taining the same dose intensity of the established weekly
regimen for both drugs. Treatment was interrupted in case
of proteinuria (urinary protein excretion, ≥ 2000 mg per
24 hours). Antihypertensive therapy was administered at
the discretion of the treating physician. BEV therapy was
not withheld or discontinued for PAC-related toxic effects.
The patients continued therapy until disease progression
or prohibitive toxic effects occurred. Patients who discon-
tinued PAC without disease progression (i.e., because of
toxic effects or at the discretion of the patient or investiga-
tor) continued BEV monotherapy until disease progres-
sion or unacceptable toxic effects occurred.BMC Cancer 2009, 9:338 http://www.biomedcentral.com/1471-2407/9/338
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Safety and efficacy
Toxicities were evaluated on days 1 and 15 of each treat-
ment cycle and graded according to the National Cancer
Institute Common Toxicity Criteria NCI-CTC, version 2.0.
Tumour response was determined by the treating physi-
cians according to WHO criteria [10] at baseline and every
12 weeks until disease progression.
Statistical analysis
Our analysis objective of was the preliminary assessment
of the efficacy and toxicity profile of the combination of
BEV and PAC in patients with ABC.
Data are expressed as median and min-max for continu-
ous variables and as percentages for categorical data. The
Kolmogorov---Smirnov test is utilized for normality anal-
ysis of the parameters. Overall survival (OS) and progres-
sion-free survival (PFS) are estimated with the Kaplan-
Meier product--limit method [11]. All tests are two-sided
with 95% significance level. The statistical analysis was
carried out using the statistical package SPSS ver. 15.00
(Statistical Package for the Social Sciences, SPSS Inc., Chi-
cago, Ill., USA).
Results
Patients
41 female and 1 male patients, who presented with ABC
between January 2007 and December 2008 were
reviewed. Median age was 57.5 years (range 33-82 years).
All patients had previously received cytotoxic chemother-
apy with taxanes and/or anthracyclines for metastatic dis-
ease. HER-2 positivity was noticed in 15 patients (35.7%).
The median number of cycles of paclitaxel administered
was 9 (range 3-12) and of bevacizumab was 21 (3-29). A
summary of baseline patient characteristics is shown in
Table 1. No patient was withdrawn from the study.
Toxicity
Grade I neutropenia was encountered in 5 patients
(11.9%) and grade II or III in 7 patients (16.6%). Only
one patient (2.4%) developed grade IV neutropenia and
one was diagnosed with febrile neutropenia. In 4 patients
with grade III or IV neutropenia the treatment dose was
reduced by 10%. Low grade anaemia (I-II) was observed
in 4 patients (9.5%) and grade I-III neuropathy was seen
in 33.3% of patients, with grade II neuropathy being the
most frequently occurring (6 patients, 14.3%). Hyperten-
sion was seen in 16.7% of patients and was managed
medically. Proteinuria was rarely clinically significant.
Thromboembolic events were infrequent overall; how-
ever, there was one death recorded due to cerebrovascular
ischaemia (stroke) related to treatment. The treatment
related adverse events are summarised in Tables 2 &3.
Efficacy
Out of the 42 patients, 3 patients (7.1%) achieved com-
plete response, while 12 patients (28.6%) had partial
response, leading to an overall response rate of 35.7%.
Impressive responses were noticed in skin lesions and two
remissions in CNS lesions were recorded. Finally, stable
disease was observed in 19 patients (45.2%), whereas 6
patients (14.3%) progressed (Table 4). At 20 months of
follow-up, the projected (Kaplan-Meier) overall survival
was approximately 70%. This implies that the median OS
is greater than 20 months, with a one year OS rate of
83.4% (Figure 1, Table 5). The median progression free
survival (PFS) was 12.1 months, with a one year PFS rate
of 51.8% (Figure 2, Table 5).
Discussion
In our analysis, 42 patients with metastatic breast carci-
noma previously treated with taxanes and/or anthracy-
Table 1: Baseline patient and disease characteristics
No. of Patients (n = 42) %
Median Age (years) 57.5
Range 33-82
HER2 status
Negative 27 64.3
Positive 15 35.7
Metastatic disease
Bone 21/42 50
Liver 17/42 40.5
Skin 16/42 38.1
Lung 12/42 28.6
CNS† 5/42 11.9
Lymph nodes 4/42 9.5
Bone marrow 1/42 2.4
Malignant pleural effusion 4/42 9.5
Malignant ascites 1/42 2.4
Line of treatment
2nd 21 50
3rd 15 35.7
4th 49 . 5
5th 24 . 8
†CNS: Central nervous system
Table 2: Treatment related adverse events
No. of Patients (n = 42)
Grade I Grade II Grade III Grade IV
Haematological
Anaemia 3 (7.1%) 1 (2.4%) - -
Neutropenia 5 (11.9%) 4 (9.5%) 3 (7.1%) 1 (2.4%)
Neuropathy 5 (11.9%) 6 (14.3) 3 (7.1%) -BMC Cancer 2009, 9:338 http://www.biomedcentral.com/1471-2407/9/338
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clines based regimens and who received a biweekly,
combination regimen of BEV and PAC as 2nd+ line of
treatment, were reviewed. Overall response rate was
35.7% and disease progression rate was 14.3%. The
median OS was greater than 20 months and the median
PFS was 12.1 months. The treatment was generally well
tolerated and toxicity was acceptable. Only one death was
recorded due to toxicity.
Anthracyclines and taxanes are the most effective agents
for treatment of hormone receptor-negative breast cancer.
The taxanes, PAC and docetaxel, have been found to be as
efficacious as anthracyclines in the first-line therapy for
ABC [5,12,13]. Even in second- and third-line settings,
PAC has demonstrated single-agent response rates of 35%
to 53% and response durations ranging from 6.8 to 7.5
months [14,15]. However, the widespread use of anthra-
cyclines and taxanes, especially PAC, in the adjuvant set-
ting has led to an increasing number of patients
presenting with advanced disease that is resistant or intol-
erant to both drugs. Although there is no standard chem-
otherapy for patients with ABC after failure of
anthracyclines and taxanes, combination chemotherapy is
the most commonly used method of treatment [16].
In a phase I/II study of 75 pretreated patients with ABC,
BEV revealed clinical activity as a single agent, with an
objective response rate of 9.3%; 17% of patients had a
response or were stable at 22 weeks [17]. A phase III trial
of capecitabine (2500 mg/m2/d on day 1--14 every 3
weeks) alone or in combination with BEV (15 mg/kg on
day 1) in 462 patients previously treated with both an
anthracycline and a taxane was well tolerated and signifi-
cantly increased the response rate (19.8% vs. 9.1%; p =
0.001). Nevertheless, this did not result into improved
progression free survival (PFS) (4.86 vs. 4.17 months) or
OS (15.1 vs. 14.5 months). It was hypothesised that the
optimal time to use an anti-angiogenic agent might be
earlier in the course of disease [7]. In the pivotal E2100
phase III trial 722 previously untreated patients with ABC
were randomised to PAC 90 mg/m2 on days 1, 8, 15 of a
28-day cycle with or without BEV 10 mg/kg on days 1 and
15. The tolerability of the combination therapy was
acceptable; hypertension rate requiring therapy on the
BEV arm was 15% vs. 1.4% in the PAC group. PFS (11.4
vs.  6.1 months, p  < 0.0001) and overall response rate
(29.8% vs. 13.8%, p < 0.0001) were significantly increased
in the combination group. Notably, there was a trend
towards improved OS in the combination arm (26.7 vs.
25.2 months; p = 0.16); nevertheless, longer follow-up is
needed to demonstrate a benefit in survival [8]. Currently,
there are insufficient data in the literature regarding the
use of the PAC and BEV combination in pretreated
patients with ABC. Our results show that the combination
of BEV and PAC in this patient population leads to an
overall response rate of 35.7%, median OS greater than 20
months and median PFS of 12.1 months. The presence of
a significant percentage of metastases with more favoura-
ble prognosis among our patients (skin, bone, lungs),
might in part explain the better, as compared to previous
reports, results observed; moreover, the lower than
reported in the literature percentage of HER2-negative
patients (eventually including dismal phenotypes, as
Basal-like, Normal-like) may also be responsible for the
somewhat improved results, although interpretation of
this observation is equivocal based on current knowledge.
Finally, response of evaluable-disease (bone, ascites, pleu-
ral effusion) sites might have been overestimated.
Conversely, it should be emphasized that, 50% of patients
were treated in third or more line; this, if confirmed by
others, would suggest that antiangiogenic therapy may
maintain a high activity even in heavily pretreated breast
cancer.
Toxicity was acceptable with easily manageable side
effects. We recorded one death due to cerebrovascular
ischaemia, possibly related to treatment, in line with
Miller et al, who report in their study a significant increase
Total overall survival (OS) of patients with ABC in the 2nd+  line of treatment, who received a modified biweekly regimen  of BEV and PAC Figure 1
Total overall survival (OS) of patients with ABC in 
the 2nd+ line of treatment, who received a modified 
biweekly regimen of BEV and PAC.
Table 3: Treatment related adverse events
No. of patients (n = 42) %
Hypertension (Grade I) 7 16.7
Proteinuria (Grade II) 2 4.8
Febrile neutropenia (Grade III) 1 2.4
Arterial thrombosis (Grade II) 1 2.4
Venous thrombosis (Grade II) 1 2.4
Toxicity related deaths 1 2.4BMC Cancer 2009, 9:338 http://www.biomedcentral.com/1471-2407/9/338
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in cerebrovascular ischemia among patients receiving
combined therapy (1.9% vs. 0.0%, p = 0.02) [8].
The main drawbacks of this study are the small number of
patients and its retrospective nature, however, the trends
observed in OS, as well as in PFS justify the need for fur-
ther prospective randomized trials. Ongoing studies, such
as the Ribbon and Ribbon 1, may confirm our results in
the future.
The biweekly BEV/PAC combination seems to be active
with acceptable toxicity and may represent an interesting
option for salvage therapy in the "exhausted" patients
with pretreated ABC. Furthermore this biweekly regimen
has a clear advantage over the weekly one in terms of qual-
ity of life and resource sparing.
Conclusion
The biweekly BEV/PAC combination seems to be active
with acceptable toxicity and may represent an interesting
option for salvage therapy-in this group of "exhausted"
patients with pretreated ABC- that needs further investiga-
tion. Furthermore this biweekly regimen has a clear
advantage over the weekly one in terms of quality of life
and resource sparing.
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